# Sine Reker Hadrup

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 97 papers | 9,461 citations | 53751 45 h-index | 42364 92 g-index |
| 107 all docs | 107 docs citations | 107 times ranked | 14488 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndromeÂ-Âa phase I clinical trial. Cancer Immunology, Immunotherapy, 2022, 71, 433-444. | 2.0 | 8 |
| 2 | Extended T-Cell Epitope Landscape in Merkel Cell Polyomavirus Large T and Small T Oncoproteins Identified Uniquely in Patients with Cancer. Journal of Investigative Dermatology, 2022, 142, 239-243.e13. | 0.3 | 3 |
| 3 | Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma. Journal of Clinical Investigation, 2022, 132, . | 3.9 | 54 |
| 4 | Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAFÂ®09b, in patients with metastatic melanoma. OncoImmunology, 2022, 11, 2023255. | 2.1 | 18 |
| 5 | Antigen-specific T cells. , 2022, , 193-208. | | 0 |
| 6 | Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials. Cancer Immunology, Immunotherapy, 2022, , 1. | 2.0 | 5 |
| 7 | Novel Molecular Targets for Hepatocellular Carcinoma. Cancers, 2022, 14, 140. | 1.7 | 8 |
| 8 | Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. Nature Communications, 2022, 13, 1935. | 5.8 | 37 |
| 9 | Fundamental immuneâ€“oncogenicity trade-offs define driver mutationÂfitness. Nature, 2022, 606, 172-179. | 13.7 | 23 |
| 10 | Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell, 2021, 184, 596-614.e14. | 13.5 | 485 |
| 11 | SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8 <sup>+</sup> T cell activation in COVID-19 patients. Science Immunology, 2021, 6, . | 5.6 | 183 |
| 12 | A user's guide to multicolor flow cytometry panels for comprehensive immune profiling. Analytical Biochemistry, 2021, 627, 114210. | 1.1 | 12 |
| 13 | T Cell Epitope Prediction and Its Application to Immunotherapy. Frontiers in Immunology, 2021, 12, 712488. | 2.2 | 27 |
| 14 | NetTCR-2.0 enables accurate prediction of TCR-peptide binding by using paired TCRÎ± and Î² sequence data. Communications Biology, 2021, 4, 1060. | 2.0 | 101 |
| 15 | Optimization in Detection of Antigenâ€Specific T Cells Through Differentially Labeled MHC Multimers. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2020, 97, 955-964. | 1.1 | 0 |
| 16 | Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers. Nature Communications, 2020, 11, 5660. | 5.8 | 55 |
| 17 | Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations. Frontiers in Immunology, 2020, 11, 373. | 2.2 | 27 |
| 18 | The T cell differentiation landscape is shaped by tumour mutations in lung cancer. Nature Cancer, 2020, 1, 546-561. | 5.7 | 74 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Empty peptide-receptive MHC class I molecules for efficient detection of antigen-specific T cells. Science Immunology, 2019, 4, . | 5.6 | 64 |
| 20 | T-cell-receptor cross-recognition and strategies to select safe T-cell receptors for clinical translation. Immuno-Oncology Technology, 2019, 2, 1-10. | 0.2 | 18 |
| 21 | Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nature Medicine, 2019, 25, 1549-1559. | 15.2 | 147 |
| 22 | Lipid Nanoparticles for Delivery of Therapeutic RNA Oligonucleotides. Molecular Pharmaceutics, 2019, 16, 2265-2277. | 2.3 | 69 |
| 23 | CD8+ T cells from patients with narcolepsy and healthy controls recognize hypocretin neuron-specific antigens. Nature Communications, 2019, 10, 837. | 5.8 | 80 |
| 24 | T cell recognition of novel shared breast cancer antigens is frequently observed in peripheral blood of breast cancer patients. OncoImmunology, 2019, 8, e1663107. | 2.1 | 9 |
| 25 | Prediction of neoepitopes from murine sequencing data. Cancer Immunology, Immunotherapy, 2019, 68, 159-161. | 2.0 | 6 |
| 26 | T-cell Responses in the Microenvironment of Primary Renal Cell Carcinomaâ€"Implications for Adoptive Cell Therapy. Cancer Immunology Research, 2018, 6, 222-235. | 1.6 | 59 |
| 27 | T cell receptor fingerprinting enables in-depth characterization of the interactions governing recognition of peptideâ€"MHC complexes. Nature Biotechnology, 2018, 36, 1191-1196. | 9.4 | 85 |
| 28 | Human endogenous retroviruses and their implication for immunotherapeutics of cancer. Annals of Oncology, 2018, 29, 2183-2191. | 0.6 | 63 |
| 29 | MuPeXI: prediction of neo-epitopes from tumor sequencing data. Cancer Immunology, Immunotherapy, 2017, 66, 1123-1130. | 2.0 | 177 |
| 30 | Evolution of MHC-based technologies used for detection of antigen-responsive T cells. Cancer Immunology, Immunotherapy, 2017, 66, 657-666. | 2.0 | 65 |
| 31 | Determining T-cell specificity to understand and treat disease. Nature Biomedical Engineering, 2017, 1, 784-795. | 11.6 | 10 |
| 32 | Preclinical evaluation of NF-ÎºB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination. Therapeutic Advances in Medical Oncology, 2017, 9, 451-464. | 1.4 | 18 |
| 33 | PD-1+ Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer. Clinical Cancer Research, 2017, 23, 5779-5788. | 3.2 | 53 |
| 34 | Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNÎ³ Signaling. Cancer Research, 2017, 77, 4562-4566. | 0.4 | 39 |
| 35 | Automated Analysis of Flow Cytometry Data to Reduce Inter-Lab Variation in the Detection of Major Histocompatibility Complex Multimer-Binding T Cells. Frontiers in Immunology, 2017, 8, 858. | 2.2 | 9 |
| 36 | An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes. Frontiers in Immunology, 2017, 8, 1566. | 2.2 | 103 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma. Oncotarget, 2017, 8, 27062-27074. | 0.8 | 26 |
| 38 | Immune Mechanisms in Myelodysplastic Syndrome. International Journal of Molecular Sciences, 2016, 17, 944. | 1.8 | 48 |
| 39 | Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. Nature Biotechnology, 2016, 34, 1037-1045. | 9.4 | 279 |
| 40 | Neoantigen landscape dynamics during human melanomaâ€“T cell interactions. Nature, 2016, 536, 91-95. | 13.7 | 387 |
| 41 | Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science, 2016, 351, 1463-1469. | 6.0 | 2,445 |
| 42 | Design and validation of conditional ligands for <scp>HLAâ€Β</scp>*08:01, <scp>HLAâ€Β</scp>*15:01, <scp>HLAâ€Β</scp>*35:01, and <scp>HLAâ€Β</scp>*44:05. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2015, 87, 967-975. | 1.1 | 21 |
| 43 | Comment on â€œ5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activityâ€. Mediators of Inflammation, 2015, 2015, 1-3. | 1.4 | 0 |
| 44 | Thinking Outside the Gate: Single-Cell Assessments in Multiple Dimensions. Immunity, 2015, 42, 591-592. | 6.6 | 67 |
| 45 | Broadening the repertoire of melanoma-associated T-cell epitopes. Cancer Immunology, Immunotherapy, 2015, 64, 609-620. | 2.0 | 8 |
| 46 | Cryopreservation of MHC multimers: Recommendations for quality assurance in detection of antigen specific T cells. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2015, 87, 37-48. | 1.1 | 19 |
| 47 | 5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies. Blood Cancer Journal, 2014, 4, e197-e197. | 2.8 | 67 |
| 48 | T-cell Responses to Oncogenic Merkel Cell Polyomavirus Proteins Distinguish Patients with Merkel Cell Carcinoma from Healthy Donors. Clinical Cancer Research, 2014, 20, 1768-1778. | 3.2 | 81 |
| 49 | Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment. Cancer Microenvironment, 2013, 6, 123-133. | 3.1 | 263 |
| 50 | High-throughput identification of antigen-specific TCRs by TCR gene capture. Nature Medicine, 2013, 19, 1534-1541. | 15.2 | 166 |
| 51 | Discovery of CD8 T cell epitopes in Merkel cell polyomavirus through combinatorial encoding with MHC multimers. , 2013, 1, P13. | | 2 |
| 52 | Effects of Ipilimumab on expanded tumor infiltrating lymphocytes in patients with stage IV malignant melanoma. , 2013, 1, . | | 0 |
| 53 | Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients. OncoImmunology, 2013, 2, e23288. | 2.1 | 25 |
| 54 | Hierarchical Bayesian mixture modelling for antigen-specific T-cell subtyping in combinatorially encoded flow cytometry studies. Statistical Applications in Genetics and Molecular Biology, 2013, 12, 309-31. | 0.2 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Conditional ligands for <scp>A</scp>sian <scp>HLA</scp> variants facilitate the definition of <scp>CD</scp>8<sup>+</sup><scp>T</scp>â€cell responses in acute and chronic viral diseases. European Journal of Immunology, 2013, 43, 1109-1120. | 1.6 | 49 |
| 56 | High frequency of T cells specific for cryptic epitopes in melanoma patients. OncoImmunology, 2013, 2, e25374. | 2.1 | 21 |
| 57 | Discovering naturally processed antigenic determinants that confer protective T cell immunity. Journal of Clinical Investigation, 2013, 123, 1976-1987. | 3.9 | 58 |
| 58 | TIL therapy broadens the tumor-reactive CD8<sup>+</sup>T cell compartment in melanoma patients. OncoImmunology, 2012, 1, 409-418. | 2.1 | 171 |
| 59 | Dissection of T-cell Antigen Specificity in Human Melanoma. Cancer Research, 2012, 72, 1642-1650. | 0.4 | 137 |
| 60 | Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunology, Immunotherapy, 2012, 61, 1791-1804. | 2.0 | 103 |
| 61 | Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers. Nature Protocols, 2012, 7, 891-902. | 5.5 | 131 |
| 62 | Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion. Cancer Immunology, Immunotherapy, 2012, 61, 1221-1231. | 2.0 | 11 |
| 63 | The antigen specific composition of melanoma tumor infiltrating lymphocytes?. OncoImmunology, 2012, 1, 935-936. | 2.1 | 5 |
| 64 | Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. Journal of Translational Medicine, 2012, 10, 169. | 1.8 | 134 |
| 65 | Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers. Journal of Autoimmunity, 2011, 37, 151-159. | 3.0 | 66 |
| 66 | Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood, 2011, 117, 2200-2210. | 0.6 | 101 |
| 67 | High-Throughput Identification of Potential Minor Histocompatibility Antigens by MHC Tetramer-Based Screening: Feasibility and Limitations. PLoS ONE, 2011, 6, e22523. | 1.1 | 36 |
| 68 | MHC-based detection of antigen-specific CD8+ T cell responses. Cancer Immunology, Immunotherapy, 2010, 59, 1425-1433. | 2.0 | 29 |
| 69 | Simultaneous Detection of Circulating Autoreactive CD8+ T-Cells Specific for Different Islet Cellâ€“Associated Epitopes Using Combinatorial MHC Multimers. Diabetes, 2010, 59, 1721-1730. | 0.3 | 187 |
| 70 | Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy, 2010, 12, 721-734. | 0.3 | 66 |
| 71 | CD8 T-cell Responses against Cyclin B1 in Breast Cancer Patients with Tumors Overexpressing p53. Clinical Cancer Research, 2009, 15, 1543-1549. | 3.2 | 15 |
| 72 | Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nature Methods, 2009, 6, 520-526. | 9.0 | 286 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Longitudinal immune monitoring of patients receiving intratumoral injection of a MART-1 T-cell receptor-transduced cell line (C-Cure 709). Cytotherapy, 2009, 11, 631-641. | 0.3 | 2 |
| 74 | Modular Nucleic Acid Assembled p/MHC Microarrays for Multiplexed Sorting of Antigen-Specific T Cells. Journal of the American Chemical Society, 2009, 131, 9695-9703. | 6.6 | 84 |
| 75 | High-Throughput T-Cell Epitope Discovery Through MHC Peptide Exchange. Methods in Molecular Biology, 2009, 524, 383-405. | 0.4 | 52 |
| 76 | The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase. PLoS ONE, 2009, 4, e6910. | 1.1 | 64 |
| 77 | Natural T-cell responses against minor histocompatibility antigen (mHag) HY following HLA-matched hematopoietic cell transplantation: what are the requirements for a â€˜goodâ€™ mHag?. Leukemia, 2008, 22, 1948-1951. | 3.3 | 2 |
| 78 | Characterization of a single peptide derived from cytochrome P450 1B1 that elicits spontaneous human leukocyte antigen (HLA)-A1 as well as HLA-B35 restricted CD8 T-cell responses in cancer patients. Human Immunology, 2008, 69, 266-272. | 1.2 | 6 |
| 79 | Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3825-3830. | 3.3 | 150 |
| 80 | Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient. Cancer Immunology, Immunotherapy, 2007, 56, 527-533. | 2.0 | 8 |
| 81 | Immune Risk Phenotypes and Associated Parameters in Very Old Humans: A Review of Findings in the Swedish NONA Immune Longitudinal Study. , 2007, , 1-14. | | 3 |
| 82 | Persistence of survivin specific T cells for seven years in a melanoma patient During domplete remission. Cancer Biology and Therapy, 2006, 5, 480-482. | 1.5 | 24 |
| 83 | Generation of peptideâ€“MHC class I complexes through UV-mediated ligand exchange. Nature Protocols, 2006, 1, 1120-1132. | 5.5 | 293 |
| 84 | Tumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cells. International Journal of Cancer, 2006, 119, 831-838. | 2.3 | 38 |
| 85 | Longitudinal Studies of Clonally Expanded CD8 T Cells Reveal a Repertoire Shrinkage Predicting Mortality and an Increased Number of Dysfunctional Cytomegalovirus-Specific T Cells in the Very Elderly. Journal of Immunology, 2006, 176, 2645-2653. | 0.4 | 447 |
| 86 | Immunogenicity of Bcl-2 in patients with cancer. Blood, 2005, 105, 728-734. | 0.6 | 60 |
| 87 | Evidence for involvement of clonally expanded CD8+ T cells in anticancer immune responses in CLL patients following nonmyeloablative conditioning and hematopoietic cell transplantation. Leukemia, 2005, 19, 2273-2280. | 3.3 | 25 |
| 88 | Spontaneous T-cell responses against peptides derived from the Taxol resistanceâ€“associated gene-3 (TRAG-3) protein in cancer patients. Cancer Immunology, Immunotherapy, 2005, 54, 219-228. | 2.0 | 15 |
| 89 | Concomitant Administration of Interleukin-2 During Therapeutic Vaccinations Against Cancer: The Good, the Bad, or the Evil?. Journal of Clinical Oncology, 2005, 23, 5265-5267. | 0.8 | 6 |
| 90 | Spontaneous Immunity against Bcl-xL in Cancer Patients. Journal of Immunology, 2005, 175, 2709-2714. | 0.4 | 38 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Identification of Novel Survivin-Derived CTL Epitopes with Different HLA-A-Restriction Profiles. Cancer Biology and Therapy, 2004, 3, 173-179. | 1.5 | 81 |
| 92 | Immunogenicity of Constitutively Active V599EBRaf. Cancer Research, 2004, 64, 5456-5460. | 0.4 | 71 |
| 93 | The Melanoma Inhibitor of Apoptosis Protein: A Target for Spontaneous Cytotoxic T Cell Responses. Journal of Investigative Dermatology, 2004, 122, 392-399. | 0.3 | 35 |
| 94 | HLA-B35-restricted immune responses against survivin in cancer patients. International Journal of Cancer, 2004, 108, 937-941. | 2.3 | 51 |
| 95 | Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Seminars in Cancer Biology, 2003, 13, 449-459. | 4.3 | 73 |
| 96 | The intercellular adhesion molecule-1 K469E polymorphism in type 1 diabetes. Immunogenetics, 2000, 52, 107-111. | 1.2 | 27 |
| 97 | Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade. Frontiers in Immunology, 0, 13, . | 2.2 | 2 |